首页> 美国卫生研究院文献>other >Exposure Matching of Pediatric Anti-infective Drugs: Review of Drugs Submitted to the Food and Drug Administration for Pediatric Approval
【2h】

Exposure Matching of Pediatric Anti-infective Drugs: Review of Drugs Submitted to the Food and Drug Administration for Pediatric Approval

机译:儿科抗感染药物的暴露匹配:提交给美国食品药品监督管理局的药物审查

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

PurposeOver the last decade, few novel antibiotics have been approved by the Food and Drug Administration (FDA) for pediatric use. For most anti-infective agents, including antibiotics, extrapolation of efficacy from adults to children is possible if the disease and therapeutic exposures are similar between the 2 populations. This approach reduces the number of studies required in children, but relies heavily on exposure matching between children and adults. Failures in exposure matching can lead to delays in pediatric approvals of new anti-infective agents. We sought to determine the extent of exposure matching, defined by a comparison of area under the concentration-time curve, between children and adults, for anti-infective drug products submitted to the FDA for approval.
机译:目的在过去的十年中,美国食品药品监督管理局(FDA)很少批准将新型抗生素用于儿科。对于大多数抗感染药,包括抗生素,如果两个人群之间的疾病和治疗暴露相似,则可以将功效从成人推算给儿童。这种方法减少了对儿童的研究数量,但在很大程度上依赖于儿童和成人之间的接触匹配。暴露匹配失败会导致小儿对新抗感染药的批准延迟。我们试图确定暴露匹配的程度,该定义由提交给FDA批准的抗感染药物产品在儿童和成人之间的浓度-时间曲线下面积的比较确定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号